Amyloid plaques drive the spread of tangles throughout a person’s brain, but much about this process remains mysterious. At this year’s AD/PD conference in Copenhagen, Denmark, speakers showed PET ...
The blood-brain border has long stymied drug development for neurodegenerative diseases. In recent years, Denali, Roche, and others have designed molecular brain shuttles that ferry investigational ...
This is an active immunotherapy strategy. ACC-001 is a conjugate of multiple short Aβ fragments linked to a carrier made of inactivated diphtheria toxin. Vanutide cridificar is designed to avoid the ...
This interactive resource organizes decades of data on biomarkers for Alzheimer's disease. Biomarker measurements from the cerebrospinal fluid and blood are curated from the primary literature and ...
Affitope AD02 is a synthetic peptide of six amino acids that mimics the N-terminus of Aβ. AFFiRiS hypothesizes that this fragment enables exclusive recognition of Aβ without cross-reacting with APP, ...
Applications will be accepted that request a single, commercially available instrument or an integrated instrumentation system. The minimum award is $50,000. There is no upper limit on the cost of the ...
Primary Papers Seubert P, Mawal-Dewan M, Barbour R, Jakes R, Goedert M, Johnson GV, Litersky JM, Schenk D, Lieberburg I, Trojanowski JQ. Detection of phosphorylated Ser262 in fetal tau, adult tau, and ...
NIH BRAIN and partner components intend to commit an estimated total of $2M in fiscal years 2025, 2026, 2027 to fund up to 8 new awards each year for this RFA, contingent upon annual appropriations.
Sergey Zubkov, Ph.D. Contact Information Sergey Zubkov, Ph.D. Odessa, Ukraine ...
Score another one for amyloid immunotherapy. The anti-pyroglutamated amyloid antibody donanemab has posted positive top-line results in the Phase 3 Trailblazer-Alz2 study, according to an Eli Lilly ...
It has been clear for a while that anti-amyloid antibodies can sweep plaque from the brain, but until now the question of whether this slows cognitive decline has remained hotly contended. Despite ...
The blood-brain barrier weakens during normal aging and in neurodegenerative disease, but the reasons are not fully understood. In the February 26 Nature, scientists led by Tony Wyss-Coray and Carolyn ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results